

Zealand announces the total number of shares and voting rights in the company as of 30 November 2015

Copenhagen, 30 November 2015 - In accordance with Section 6 of the *Danish Statutory Order on Issuers' Disclosure Obligations*, Zealand announces the total number of shares and voting rights in the company at the end of a calendar month in which changes to the share capital have occurred.

With reference to Company Announcements no. 47 / 2015 dated 4 November 2015 and no. 49 / 2015 dated 13 November 2015 informing of increases in the share capital and voting rights after exercise of employee warrants, the table below provides the total number of shares and voting rights in Zealand as of 30 November 2015.

	Number of shares (nominal value of DKK 1)	Nominal value in DKK	Number of votes
Shares	24,282,299	24,282,299	24,282,299



For further information, please contact:

Hanne Leth Hillman, Senior Vice President for Investor Relations and Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.

Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is marketed globally outside the US as Lyxumia® by Sanofi and under regulatory review in the US. The license collaboration with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus®) which is on track for regulatory submission in the US in December 2015 and in the European Union in Q1 2016.

The proprietary pipeline includes; *danegaptide* for ischemic reperfusion Injuries in Phase II development; *ZP1848* for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, *ZP4207*, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as *several preclinical peptide therapeutics*.

The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand's business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma